Multiple New Studies Demonstrate T2 Biosystems’ Diagnostics Improve Detection of Sepsis Causing Pathogens Over Blood Culture-based Diagnostics

U.S. and EU studies demonstrate that T2Dx diagnostics enable getting patients on the right therapy faster, improving outcomes, enhancing stewardship, and reducing the cost of care
LEXINGTON, Mass., March 28, 2018 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products, announces the publication of four new, peer-reviewed studies that demonstrate the clinical and performance advantages of the T2Dx® Instrument over blood culture. The T2Dx Instrument runs the T2Candida® and T2Bacteria® Panels, which detect and identify pathogens that cause sepsis. Sepsis is a life-threatening illness that kil…


Leave a Reply

Your email address will not be published.